المؤلفون: A. Laryukov V., R. Hasanov Sh., Z. Afanasyeva A., E. Laryukova K., А. Ларюков В., Р. Хасанов Ш., З. Афанасьева А., Е. Ларюкова К.

المصدر: Siberian journal of oncology; Том 20, № 5 (2021); 100-107 ; Сибирский онкологический журнал; Том 20, № 5 (2021); 100-107 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-5

مصطلحات موضوعية: non-small cell lung cancer, bone metastases, positron emission computed tomography, magnetic resonance computed tomography, немелкоклеточный рак легкого, метастазы в кости, позитронно-эмиссионная компьютерная томография, магнитно-резонансная компьютерная томография

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1920/922; Давыдов М.И., Полоцкий Б.Е. Рак легкого. М., 2003. 454 с.; Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2019 году. М., 2020. 239 с.; Ejima Y., Matsuo Y., Sasaki R. The current status and future of radiotherapy for spinal bone metastases. J Orthop Sci. 2015 Jul; 20(4): 585–92. doi:10.1007/s00776-015-0720-x.; Ларюков А.В., Ларюкова Е.К. Особенности отдаленного метастазирования периферического немелкоклеточного рака легкого. Практическая медицина. 2012; 7(62): 163–165.; Machado Medeiros T., Altmayer S., Watte G., Zanon M., Basso Dias A., Henz Concatto N., Hoefel Paes J., Mattiello R., de Souza Santos F., Mohammed T.L., Verma N., Hochhegger B. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Eur Radiol. 2020 Jul; 30(7): 3641–3649. doi:10.1007/s00330-020-06703-1.; Ohno Y., Takeshi Y., Takenaka D., Koyama H., Aoyagi K., Yui M. Comparison of Diagnostic Accuracy for TNM Stage Among Whole-Body MRI and Coregistered PET/MRI Using 1.5-T and 3-T MRI Systems and Integrated PET/CT for Non-Small Cell Lung Cancer. Am J Roentgenol. 2020 Nov; 215(5): 1191–1198. doi:10.2214/AJR.19.22565.; Крживицкий П.И.,Канаев С.В., Семенов И.И., Новиков С.Н.Лучевые и ядерные методы диагностики метастатических поражений скелета. Радиационная онкология и ядерная медицина. 2012; 2: 72– 77.; Сергеев Н.И., Нуднов Н.В. Дифференциальная диагностика доброкачественных и злокачественных поражений позвоночника по данным магнитно-резонансной томографии с использованием болюсного контрастного усиления. Вестник Российского научного центра рентгенорадиологии. 2012; 2(3): 30–35.; Dickinson F., Liddicoat A., Dhingsa R., Finlay D. Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. Clin Radiol. 2000 Aug; 55(8): 653. doi:10.1053/crad.2000.0418.; Berquist T.H. MRI of the musculoskeletal system. Lippincott Williams & Wilkins, 2006. 204 p.; Li C., Liu Z.S., Du X.M., He L., Chen J., Wang W., Sun F., Du F., Luo Z.G., Xue Z.L., Zhao Y., Zhou C.W. Clinical value of whole-body magnetic resonance diffusion weighted imaging on detection of malignant metastases. Chin Med Sci J. 2009 Jun; 24(2): 112–6. doi:10.1016/s1001-9294(09)60072-9.; Сергеев Н.И., Котляров П.М., Солодкий В.А., Овчинников В.И. Магнитно-резонансная томография в оценке эффективности химиолучевого лечения при вторичном поражении позвоночника, костей таза. Медицинская визуализация. 2013; 1: 109–114.; https://www.siboncoj.ru/jour/article/view/1920

الاتاحة: https://www.siboncoj.ru/jour/article/view/1920
https://doi.org/10.21294/1814-4861-2021-20-5-100-107

المؤلفون: D. Pasynkov V., M. Tukhbatullin G., R. Khasanov Sh., Д. Пасынков В., М. Тухбатуллин Г., Р. Хасанов Ш.

المصدر: Medical Visualization; Том 25, № 4 (2021); 93-105 ; Медицинская визуализация; Том 25, № 4 (2021); 93-105 ; 2408-9516 ; 1607-0763

مصطلحات موضوعية: mammography, fatty breast, computer-aided detection system, breast cancer, interval cancer, маммография, жировая паренхима, система компьютерной диагностики, рак молочной железы, интервальный рак

وصف الملف: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/1040/689; https://medvis.vidar.ru/jour/article/downloadSuppFile/1040/1218; https://medvis.vidar.ru/jour/article/downloadSuppFile/1040/1219; https://medvis.vidar.ru/jour/article/downloadSuppFile/1040/1220; https://medvis.vidar.ru/jour/article/downloadSuppFile/1040/1221; https://medvis.vidar.ru/jour/article/downloadSuppFile/1040/1222; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J. Clin. 2018; 68: 394– 424. http://doi.org/10.3322/caac.21492.; Canto J.G., Kiefe C.I. Age-Specific Analyses of Breast Cancer Versus Heart Disease Mortality in Women. Am. J. Cardiol. 2014; 113: 410–411. http://doi.org/10.1016/j.amjcard.2013.08.055; Состояние онкологической помощи населению России в 2018 году / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., МНИОИ им. П.А. Герцена, филиал ФГБУ “НМИЦ радиологии” Минздрава России, 2019.; Seely J.M., Alhassan T. Screening for breast cancer in 2018 – what should we be doing today? Curr. Oncol. 2018; 25 (Suppl. 1): S115–S124. http://doi.org/https://doi.org/10.3747/co.25.3770; Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L., Bouvard V., Bianchini F. et al. Breast-cancer screening – viewpoint of the IARC Working Group. N. Engl. J. Med. 2015; 372: 2353–2358. http://doi.org/10.1056/NEJMsr1504363; Breast-cancer screening with mammography in women aged 40–49 years Swedish Cancer Society and the Swedish National Board of Health and Welfare. Int. J. Cancer. 1996; 68: 693–699.; Пасынков Д.В., Егошин И.А., Колчев А.А., Клюшкин И.В., Бусыгина О.В. Сравнительный анализ диагностической ценности систем компьютерного анализа маммограмм I и II поколений. Медицинская визуализация. 2017; 21 (1): 90–102. http://doi.org/10.24835/1607-0763-2017-1-90-102; Пасынков Д.В., Егошин И.А., Колчев А.А., Клюшкин И.В., Пасынкова О.О. Эффективность системы компьютерного анализа маммограмм в диагностике вариантов рака молочной железы, трудно выявляемых при скрининговой маммографии. REJR. 2019; 9 (2): 107–118. http://doi.org/10.21569/2222-7415-2019-9-2-107-118; Egoshin I., Pasynkov D., Kolchev A., Kliouchkin I., Pasynkova O. Asegmentationapproachformammographic images and its clinical value (2018). 2017 IEEE International Conference on Microwaves, Antennas, Communications and Electronic Systems, COMCAS 2017, 2018-January: 1–6. http://doi.org/10.1109/COMCAS.2017.8244764; Shaevitch D., Taghipour S., Miller A.B., Montgomery N., Harvey B. Tumor size distribution of invasive breast cancers and the sensitivity of screening methods in the Canadian National Breast Screening Study. J. Can. Res. Ther. 2017; 13: 562–569. http://doi.org/10.4103/0973-1482.174539; Лабазанова П.Г., Рожкова Н.И., Бурдина И.И., Запирова С.Б., Мазо М.Л., Микушин С.Ю. и др. Маммографическая плотность и риск развития рака молочной железы. Взгляд на историю изучения вопроса. REJR.2020;10(2):205–222.http://doi.org/10.21569/2222-7415-2020-10-2-205-222; Miglioretti D.L., Zhu W., Kerlikowske K., Sprague B.L., Onega T., Buist D.S. et al. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status. JAMA Oncol. 2015; 1 (8): 1069–1077. http://doi.org/10.1001/jamaoncol.2015.3084; Peer P.G., van Dijck J.A., Hendriks J.H., Holland R., Verbeek A.L. Age-dependent growth rate of primary breast cancer. Cancer. 1993; 71 (11): 3547–5351.; Tubtimhin S, Promthet S, Suwanrungruang K, Supaattagorn P. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data. Asian Pac. J. Cancer Prev. 2018; 19 (11): 3167–3174. http://doi.org/10.31557/APJCP.2018.19.11.3167; Гажонова В.Е., Ефремова М.П., Дорохова Е.А. Возможности ультразвуковой томографии в прогнозировании течения рака молочной железы (РМЖ) – молекулярная классификация РМЖ. Поволжский онкологический вестник. 2016; 24 (2): 26–32.; Calas M.J.G., Gutfilen B., Pereira W.C.A. CAD and mammography: why use this tool? Radiol. Bras. 2012; 45 (1): 46–52. http://doi.org/10.1590/S0100-39842012000100011; https://medvis.vidar.ru/jour/article/view/1040

الاتاحة: https://medvis.vidar.ru/jour/article/view/1040
https://doi.org/10.24835/1607-0763-1040

المؤلفون: A. Isyangulova Z., R. Khasanov Sh., R. Enikeev F., А. Исянгулова З., Р. Хасанов Ш., Р. Еникеев Ф.

المصدر: Malignant tumours; Том 9, № 4 (2019); 49-58 ; Злокачественные опухоли; Том 9, № 4 (2019); 49-58 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: neuroendocrine tumor, targeted therapy, carcinoid, pancreatic cancer, gastrointestinal cancer, нейроэндокринная опухоль, таргетная терапия, карциноид, рак поджелудочной железы, рак желудочно-кишечного тракта

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/685/481; Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus / Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C. et al. // Cancer Treat. 2016. V. 47. P. 32 – 45.; One hundred years after «carcinoid»: epidemiology of and prognostiс factors for neuroendocrine tumors in 35,825 cases in the United States / Yao J., Hassan M., Phan A., Dagohoy C., Leary C., Mares JE. et al. // Clin. Oncol. 2008. V. 26. N18. P. 3063 – 3072.; Горбунова В. А. Нейроэндокринные опухоли. Общие принципы диагностики и лечения. М.: Кодекс, 2015. 456 с.; UKNETwork for neuroendocrine tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours / Ramage J., Davies A., Ardill J. et al. // Gut. 2005. V. 54. N4. P. 1 – 16.; Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival / Halfdanarson T., Rabe K., Rubin J. et al. // Annals of Oncology. 2008. V. 19. N10. P. 1727 – 1733.; Modlin I. M., Lye K. D., Kidd M. A. 5‑decade analysis of 13,715 carcinoid tumors // Cancer. 2003. V. 97. P. 934 – 959.; Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study // Gastroenterology. 2007. V. 132. P. 899 – 904.; Population-based study of islet cell carcinoma / Yao J., Eisner M., Leary C. et al. // Ann Surg Oncol. 2007. V. 14. P. 492 – 500.; Moertel C., Kvols L., O’Connell M., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms // Cancer. 1991. V. 68. P. 227 – 232.; Moertel C., Hanley J. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome // Cancer clinical trials. 1979. V. 2. P. 327 – 334.; Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии / под ред. В. М. Моисеенко. // Злокачественные опухоли. Спецвыпуск. 2019. 776 с.; O’Toole D., Kiaуmanesh R., Caplin M. ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update // Neuroendocrinology. 2016. V. 103. P. 117 – 118.; Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents // Annals Oncology. 2006. V. 17. N12. P. 1733 – 1742.; Wimmel A., Wiedenmann B., Rosewicz S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells // Gut. 2003. V. 52. P. 1308 – 1316.; Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis / von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K, et al. // Natl Cancer Inst. 2003. V. 95. P. 437 – 448.; Chaudhry A., Papanicolaou V., Oberg K., Heldin C., Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system // Cancer Res. 1992. V. 52. P. 1006 – 1012.; Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., Fehmann H. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours // Eur J Clin Invest. 2000. V. 30. P. 729 – 739.; Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells / von Wichert G., Jehle P., Hoeflich A., Koschnick S., Dralle H, Wolf E. et al. // Cancer Res. 2000. V. 60. P. 4573 – 4581.; Nilsson O., Wangberg B., Theodorsson E., Skottner A., Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth? // Int J Cancer. 1992. V. 51. P. 195 – 203.; Zhang H., Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor // Expert Opin Investig Drugs. 2004. V. 13. P. 1569 – 1577.; Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors / Metz, David C. et al. // Gastroenterology. 2008. V. 135. N5. P. 1469 – 1492.; Wiedmann M., Caca K. Molecularly targeted therapy for gastrointestinal cancer // Curr Cancer Drug Targets. 2005. V. 5. P. 171 – 193.; Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway // Anticancer Drugs. 2006. V. 17. P. 487 – 494.; Dancey J. Therapeutic targets: MTOR and related pathways // Cancer Biol Ther. 2006. V. 5. P. 1065 – 1073.; EGFR targeting of solid tumors / Rocha-Lima C., Soares H., Raez L. et al. // Cancer Control. 2007. V. 14. P. 295 – 304.; Harari P. Epidermal growth factor receptor inhibition strategies in oncology // Endocr Relat Cancer. 2004. V. 11. P. 689 – 708.; Bjornsti M., Houghton P. The TOR pathway: a target for cancer therapy // Nat Rev Cancer. 2004. V. 4. P. 335 – 348.; BAY 43 – 9006 exhibits broad spectrum oral antitumor activity and targets the RAF / MEK / ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis / Wilhelm S., Carter C., Tang L., Wilkie D., McNabola A., Rong H. et al.// Cancer Res. 2004. V. 64. P. 7099 – 7109.; Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy / Ciardiello F., Troiani T., Bianco R., Orditura M., Morgillo F., Martinelli E. et al. // Annals of Oncology. 2006. V. 17. N 7. P. 109 – 114.; Maione P., Gridelli C., Troiani T., Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC// Oncologist. 2006. V. 11. P. 274 – 284.; Burgaud JL, Baserga R. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor // Exp Cell Res. 1996. V. 223. P. 412 – 419.; Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor / Gilmore A., Valentijn A., Wang P., Ranger A., Bundred N., O’Hare M. et al.//J Biol Chem. 2002. V. 277. P. 27643 – 27650.; Jain R., Duda D., Clark J., Loeffler J. Lessons from phase III clinical trials on anti-VEGF therapy for cancer // Nat Clin Pract Oncol. 2006. V. 3. P. 24 – 40.; Morabito A., De Maio E., Di Maio M., Normanno N., Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions // Oncologist. 2006. V. 11. P. 753 – 764.; Hopfner M., Sutter A., Gerst B., Zeitz M., Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839) // Br J Cancer. 2003. V. 89. P. 1766 – 1775.; Hopfner M., Baradari V., Huether A., Schofl C., Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours // Endocr Relat Cancer. 2006. V. 13. P. 135 – 149.; Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors / Zhang J., Jia Z., Li Q., Wang L., Rashid A, Zhu Z. et al. // Cancer. 2007. V. 109. P. 1478 – 1486.; Pavel M., Hassler G., Baum U., Hahn E., Lohmann T., Schuppan D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas // Clin Endocrinol (Oxf). 2005. V. 62. P. 434 – 443.; Carmeliet P., Jain R. Molecular mechanisms and clinical applications of angiogenesis // Nature 473. 2011. P. 298 – 307.; Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect / Kasuya K., Nagakawa Y., Suzuki M., Tanaka H., Ohta H., Itoi T. et al. // Exp Ther Med 2. 2011. P. 1047 – 1052.; Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors / Chan J., Stuart K., Earle C., Clark J., Bhargava P., Miksad R. et al. // J Clin Oncol. 2012. V. 30. P. 2963 – 2968.; Reinacher-Schick, ASCO-update 2015 — highlights of the 51 meeting of the american society of clinical oncology // Lorenzen S., Arnold D., Fottner C., Leichsenring J., Moehler M., Seufferlein T., et al. //ASCO 2015, Z Gastroenterol. 2016. V. 54. N 02. P. 167 – 172.; (2015b) Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) / Kulke M., Niedzwiecki D., Foster N., Fruth B., Kunz P., Kennecke H. et al.// J Clin Oncol. 2015. V. 33. N 15. P. 4005.; Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) / Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen F. Kennecke et al. // J Clin Oncol. 2015. V. 33. N 15. P. 4005.; Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518 / Yao J., Guthrie K., Moran C. et al. // J Clin Oncol. 2017. doi:10.1200 / JCO. 2016. V. 70. P. 4072; Перспективы использования бевацизумаба при НЭО. Клинический случай / Г. С. Емельянова, Н. Ф. Орел, В. А. Горбунова, А. А. Коломейцева, А. А. Кузнецова, А. Е. Кузьминов и др. // Сибирский онкологический журнал. 2017. Т. 16. № 6. C. 100 – 104.; Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study / Berruti A., Fazio N., Ferrero A., Brizzi M., Volante M., Nobili E. et al. // BMC Cancer. 2014. V. 14. P. 184.; Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) — a phase II non-randomised trial / Mitry E., Walter T., Baudin E., Kurtz J. E., Ruszniewski P., Dominguez-Tinajero S. et al. // Eur J Cancer. 2014. V. 50. N 18. P. 3107 – 3115.; Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma / Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M. et al. // J Exp Med 207. 2010. P. 491 – 503.; Sitohy B., Nagy J., Dvorak H. Anti-VEGF / VEGFR therapy for cancer: Reassessing the target // Cancer Res 72. 2012. P. 1909 – 1914.; Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericytemediated endothelial cell survival mechanisms / Erber R., Thurnher A., Katsen A., Groth G., Kerger H., Hammes H. et al. // FASEB J 18. 2004. P. 338 – 340.; Wilhelm S., Chien D. BAY 43 – 9006: preclinical data // Curr Pharm Des. 2002. V. 8. P. 2255 – 2257.; Role of Raf kinase in cancer: therapeutic potential of targeting the Raf / MEK / ERK signal transduction pathway / Gollob J., Wilhelm S., Carter C., Kelley S. //Semin Oncol. 2006. V. 33. P. 392 – 406.; Sorafenib blocks the RAF / MEK / ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC / PRF / 5 / Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D. et al. // Cancer Res. 2006. V. 66. P. 11851 – 11858.; Hobday TJ, Rubin J, Holen K. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study // Clin Oncol. 2007, ASCO Annual Meeting Proceedings Part 1. 2007. V. 25. N 18. P. 4504.; Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors / Matthew H. Kulke, Heinz-Josef Lenz, Neal J. Meropol et al. // Clin Oncol. 2008. V. 20. P. 3404 – 3410.; Sunitinib malate for the treatment of pancreatic neuroendocrine tumors Raymond E., Dahan L., Raoul J. et al. // N Engl J Med. 2011. V. 364. Р. 501 – 513.; Motzer R., Bukowski R. Targeted therapy for metastatic renal cell carcinoma // Clin Oncol. 2006. V. 24. P. 5601 – 5608.; Kulke M., Bergsland E., Ryan D. A Phase II study to evaluate the safety and efficacy of SU11248 in patients with unresectable neuroendocrine tumors // Proc Am Soc Clin Oncol. 2003. V. 22. P. 958.; A phase two study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NET) // Kulke M., Lenz H., Meropol N., Posey J., Ryan D., Picus J. et al. // J Clin Oncol. 2005. V. 23. P. 4008.; Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) / Raymond E., Niccoli-Sire P., Bang Y. et al. // ASCO Gastrointestinal Cancers Symposium. Book of abstracts. 2010. Abstract 127.; Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose «chemo-switch» regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cance // Clin Oncol. 2005. V. 23. P. 939 – 952.; Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models / Yao V., Sennino B., Davis R. et al.// Eur J Cancer. 2006. V. 4. P. 27 – 28.; Activity of sunitinib in patients with advanced neuroendocrine tumors / Kulke M., Lenz H., Meropol N. et al. // Clin Oncol. 2008. V. 26. P. 3403 – 3410.; Phase 11 study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) / Okusaka T., Ito T., Nishida T. et al. // Clin Oncol. 2012. V. 30. P. 381.; Chan J., Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors// Curr Treat Options Oncol. 2014. V. 15. N3. P. 365 – 379. doi:10.1007 / s11864‑014‑0294‑4.; Симоненко В. Б., Дулин П. А., Маканин М. А. Возможности таргетной терапии нейроэндокринных опухолей // Клиническая медицина. 2014. Т. 92. № 8. С. 5 – 14.; mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates / O’Reilly K., Rojo F., She Q., Solit D., Mills G., Smith D. et al. // Akt. Cancer Research 66. 2006. P. 1500 – 1508.; A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR vs placebo + octreotide lar in patients with advanced neuroendocrine tumors (NET) (RADIANT-2) / Pavel M., Hainsworth J., Baudin E. et al. // 35th ESMO Congress. Book of abstracts. 2010. Abstract LBA8.; Everolimus treatment for neuroendocrine tumors: latest results and clinical potential / Pusceddu S., Verzoni E., Prinzi N. et al. // Therapeutic Advances in Medical Oncology. 2017. V. 9. N 3. P. 183 – 188. doi:10.1177 / 1758834016683905.; Everolimus for advanced pancreatic neuroendocrine tumors / Yao J., Shah M., Ito T. et al. // N Engl J Med. 2011. V. 364. P. 514 – 523.; Кузьминов А. Е., Полозкова С. А., Орел Н. Ф., Горбунова В. А. Нейроэндокринные опухоли // Эффективная фармакотерапия. Онкология, гематология и радиология. 2012. N1. С. 44 – 48.; A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3) / Yao J., Shah M., Ito T. et al. // 35th ESMO Congress. Book of abstracts. 2010. Abstract LBA9.; Jensen R., Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors // N Engl J Med. 2011. V. 364. P. 564 – 565.; Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study / Yao C., Fazio N., Singh S., Buzzoni R., Carnaghi C., Wolin E. et al. // The Lancet. 5 – 11 March 2016. V. 387. N10022. P. 968 – 977.; Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial / Pavel M., Singh S., Strosberg J., Bubuteishvili-Pacaud L., Degtyarev E., Neary M. et al. // The Lancet. October 2017. V. 18, N10, P. 1411 – 1422.; Chan J., Kulke M. Progressing in the treatment of neuroendocrine tumors // Curr. Oncol. Rep. 2009. V. 11. P. 193 – 199.; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives / Herrera-Martínez, Aura D et al.// Drugs. 2019. V. 79. N1. P. 21 – 42.; https://www.malignanttumors.org/jour/article/view/685

الاتاحة: https://www.malignanttumors.org/jour/article/view/685
https://doi.org/10.18027/2224-5057-2019-9-4-49-58

المؤلفون: A. Isyangulova Z., R. Khasanov Sh., R. Enikeev F., M. Gordiev G., А. Исянгулова З., Р. Хасанов Ш., Р. Еникеев Ф., М. Гордиев Г.

المصدر: Siberian journal of oncology; Том 18, № 5 (2019); 80-85 ; Сибирский онкологический журнал; Том 18, № 5 (2019); 80-85 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-5

مصطلحات موضوعية: pancreatic neuroendocrine tumors, carcinoid tumors, differentiation grade, tumor stage, targeted therapy, somatostatin, нейроэндокринные опухоли поджелудочной железы, карциноид, степень дифференцировки, стадия процесса, таргетная терапия, соматостатин

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1193/671; Strosberg J.R., Coppola D., Klimstra D.S., Phan A.T., Kulke M.H., Wiseman G.A., Kvols L.K.; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug; 39(6): 799–800. doi:10.1097/MPA.0b013e3181ebb56f.; Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after «carcinoid»: epidemiology of and prognostiс factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18): 3063–72. doi:10.1200/JCO.2007.15.4377.; Горбунова В.А. Нейроэндокринные опухоли. Общие принципы диагностики и лечения. М., 2015, 456.; Ramage J.K., Davies A.H., Ardill J., Bax N., Caplin M., Grossman A., Hawkins R., McNicol A.M., Reed N., Sutton R., Thakker R., Aylwin S., Breen D., Britton K., Buchanan K., Corrie P., Gillams A., Lewington V., McCance D., Meeran K., Watkinson A.; UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005 Jun; 54 Suppl 4: iv1–16. doi:10.1136/gut.2004.053314.; Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008 Oct; 19(10): 1727–33. doi:10.1093/annonc/mdn351.; Kim M.K. Neuroendocrine Tumors: A Multidisciplinary Approach. Gastroenterology. 2017; 152(4): 910. doi: https://doi.org/10.1053/j.gastro.2017.01.023.; Klimstra D., Arnold R., Capella C. Neuroendocrine neoplasms of the pancreas. WHO Classification of Tumors of the Digestive System. 4th Ed. Lyon: IARC. 2010; 12: 322.; Oberg K. Neuroendocrine gastrointestinal tumors A condensed overview of diagnosis and treatment. Ann Oncol. 1999; 10(2): S3–S8. doi:10.1093/annonc/10.suppl_2.s3.; Симоненко В.Б., Дудин П.А., Маканин М.А. Нейроэндокринные опухоли. М., 2010, 237.; Shkarban V., Nichitaylo M., Scums A. Surgical treatment of malignant nonfunctioning neuroendocrine tumors of the pancreas. Ann Oncol. 2013 June; 24(4): 85. doi:10.1093/annonc/mdt203.170.; Öberg K.U., Knigge D., Kwekkeboom A., Perrenon behalf of the ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012; 23(7): 24–30. doi:10.1093/annonc/mds295.; Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19(10): 1727–33. doi:10.1093/annonc/mdn351.; Moertel C.G., Kvols L.K., O’Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68: 227–232. doi:10.1002/1097-0142(19910715)68:23.0.co;2-i.; Vilar E., Salazar R., Pérez-García J., Cortes J., Oberg K., Tabernero J. Chemotherapy and role of the proliferation marker ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14: 221–232. doi:10.1677/ERC-06-0074.; Childs A., Kirkwood A., Edeline J., Luong T.V., Watkins J., Lamarca A., Alrifai D., Nsiah-Sarbeng P., Gillmore R., Mayer A., Thirlwell C., Sarker D., Valle J.W., Meyer T. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocr Relat Cancer. 2016; 563–570. doi:10.1530/ERC-16-0099.; Rinke A., Müller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Bläker M., Harder J., Arnold C., Gress T., Arnold R.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1; 27(28): 4656–63. doi:10.1200/JCO.2009.22.8510.; Caplin M.E., Pavel M., Ruszniewski P. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med. 2014 Oct 16; 371(16): 1556–7. doi:10.1056/NEJMc1409757.; Yao J.C., Shah M.H., Ito T. A randomized, double-blind, placebocontrolled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). 35th ESMO Congress; 2010 Oct 8–12; Milan. LBA9.; Симоненко В.Б., Дулин П.А., Маканин М.А. Возможности таргетной терапии нейроэндокринных опухолей. Клиническая медицина. 2014; 92(8): 5–14.; Wimmel A., Wiedenmann B., Rosewicz S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells. Gut. 2003 Sep; 52(9): 1308–16. doi:10.1136/gut.52.9.1308.; von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., Wiedenmann B., Hocker M., Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003 Mar 19; 95(6): 437–48. doi:10.1093/jnci/95.6.437.; Chaudhry A., Papanicolaou V., Oberg K., Heldin C.H., Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res.1992; 52: 1006–1012.; Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., Fehmann H.C. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest. 2000; 30: 729–739.; von Wichert G., Jehle P.M., Hoeflich A., Koschnick S., Dralle H., Wolf E., Wiedenmann B., Boehm B.O., Adler G., Seufferlein T. Insulinlike growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000; 60: 4573–4581.; Nilsson O., Wangberg B., Theodorsson E., Skottner A., Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth? Int J Cancer. 1992; 51: 195203. doi:10.1002/ijc.2910510206.; Zhang H., Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs. 2004 Dec; 13(12): 1569–77. doi:10.1517/13543784.13.12.1569.; Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. J Clin Oncol. 2008 Jul 10; 26(20): 3403–10. doi:10.1200/JCO.2007.15.9020.; Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., LombardBohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6): 501–13. doi:10.1056/NEJMoa1003825.; Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J. WHO classification of tumours of endocrine organs. 4th edn. Lyon. IARC Press. 2017.; Делекторская В.В. Нейроэндокринные новообразования поджелудочной железы: новые аспекты морфологической классификации (Всемирная организация здравоохранения, 2017). Успехи молекулярной онкологии. 2017; 4(3): 104–108.; Modlin I.M., Gustafsson B.I., Moss S.F., Pavel M., Tsolakis A.V., Kidd M. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010 Sep; 17(9): 2427–43. doi:10.1245/s10434-010-1006-3.; Моисеенко В.М. Злокачественные опухоли: практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO). М., 2017, 656.; https://www.siboncoj.ru/jour/article/view/1193

الاتاحة: https://www.siboncoj.ru/jour/article/view/1193
https://doi.org/10.21294/1814-4861-2019-18-5-80-85

المؤلفون: М. Ulyanin Yu., G. Basiashvili Т., R. Khasanov Sh., М. Burmistrov V., I. Gataullin G., М. Ульянин Ю., Г. Басиашвили Т., Р. Хасанов Ш., М. Бурмистров В., И. Гатауллин Г.

المصدر: Siberian journal of oncology; № 5 (2015); 30-36 ; Сибирский онкологический журнал; № 5 (2015); 30-36 ; 2312-3168 ; 1814-4861 ; undefined

مصطلحات موضوعية: bladder cancer, transurethral en block resection of the bladder, treatment outcomes, поверхностный рак мочевого пузыря, трансуретральная резекция мочевого пузыря единым блоком, результаты лечения

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/146/148; Державец Л.А. Лабораторные показатели и выживаемость пациентов, страдающих раком мочевого пузыря // Сибирский онкологический журнал. 2013. № 4. С. 12–16.; Злокачественные новообразования в России в 2012 г. / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. 250 с.; Мартов А.Г., Ергаков Д.В., Байков Н.А., Поминальная В.М., Соломатов И.А. Трансуретральное удаление опухолей мочевого пузыря единым блоком // Онкоурология. 2015. Т. 1, № 1. С. 41–49.; Allard P., Bernard P., Fradet Y., Tetu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index // Br. J. Urol. 1998. Vol. 81 (5). P. 692–698.; Domínguez G., Carballido J., Silva J., Silva J.M., García J.M., Menéndez J., Provencio M., España P., Bonilla F. p14ARF promoter hypermetylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients // Clin. Cancer Res. 2002. Vol. 8 (4). P. 980–985.; Epstein J.I., Amin M.B., Reuter V.R., Mostofi F.K. The world health organization/international society of urological patology consensus classification of urotelial (transitional cell) neoplasms of the urinary bladder // Am. J. Surg. Pathol. 1998. Vol. 22 (12). P. 1435–1448.; Herr H.W., Donat M.S. Quality control in transurethral resection of bladder tumors // BJU Int. 2008. Vol. 102 (9. Pt. B). P. 1242–1246. doi:10.1111/j.1464-410X.2008.07966.x.; Hu Z., Mudaliar K., Quek M.L., Paner G.P., Barkan G.A. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence // Ann. Diagn. Pathol. 2014. Vol. 18 (2). P. 49–52. doi:10.1016/j.anndiagpath.2013.11.002.; Kawada T., Ebihara K., Suzuki T., Imai K., Yamanaka H. A new technique for transurethral resection of bladder tumors: rotational tumor resection using a new arched electrode // J. Urol. 1997. Vol. 157 (6). P. 2225–2226.; Lodde M., Lusuardi L., Palermo S., Signorello D., Maier K., Hohenfellner R., Pycha A. En bloc transurethral resection of bladder tumors: use and limits // Urology. 2003. Vol. 62 (6). P. 1089–1091.; Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., Palou J., Algaba F., Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence // J. Urol. 2000. Vol. 164 (3. Pt 1.) P. 680–684.; Muto G., Collura D., Giacobbe A., D’Urso L., Muto G.L., Demarchi A., Coverlizza S., Castelli E. Thulium:yttrium-aluminum-garnet laser for en bloc resection of bladder cancer: clinical and histopathologic advantages // J. Urology. 2014. Vol. 83 (4). P. 851–855. doi:10.1016/j.urology.2013.12.022.; Naselli A., Introini C., Germinale F., Spina B., Puppo P. En bloc transurethral resection of bladder lesions: a trick to retrieve specimens up to 4.5 cm // BJU Int. 2012. Vol. 109 (6). P. 960–963. doi:10.1111/j.1464410X.2012.10982.x.; Saito S. Transurethral en bloc resection of bladder tumors // J. Urol. 2001. Vol. 166 (6). P. 2148–2150.; Upadhyay R., Kapoor R., Srivastava A., Krishnani N., Mandhani A. Does En-bloc transurethral resection of bladder tumor give a better yield in terms of presence of detrusor muscle in the biopsy specimen? // Indian J. Urol. 2012. Vol. 28 (3). P. 275–279. doi:10.4103/0970-1591.102700.; https://www.siboncoj.ru/jour/article/view/146; undefined

الاتاحة: https://www.siboncoj.ru/jour/article/view/146

المؤلفون: M. Ulyanin M., G. Basiashvili Т., R. Khasanov Sh., I. Gataullin G., M. Burmistrov V., G. Khayrullina R., M. Ульянин Ю., Г. Басиашвили Т., Р. Хасанов Ш., И. Гатауллин Г., М. Бурмистров В., Г. Хайруллина Р.

المصدر: Cancer Urology; Том 11, № 4 (2015); 42-50 ; Онкоурология; Том 11, № 4 (2015); 42-50 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-4

مصطلحات موضوعية: bladder cancer, superficial bladder cancer, transurethral resection of bladder, transurethral resection of bladder en block, recurrence of bladder cancer, complications after transurethral resection, proper muscularis mucosa, T1a, T1b, T1c, рак мочевого пузыря, поверхностный рак мочевого пузыря, трансуретральная резекция мочевого пузыря, трансуретральная резекция мочевого пузыря единым блоком, рецидив рака мочевого пузыря, осложнения после трансуретральной резекции, собственная мышечная пластинка слизистой оболочки, стадии T1a

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/473/489; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/473/111; Состояние онкологической помощи населению России в 2012 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013. [Incidence of malignant neoplasms in Russia in 2012. Eds. by: А.D. Kaprin, V.V. Starinskiy, Moscow, 2013. (In Russ.)].; Kausch von Schmeling I. Diagnosis of and therapy for non-muscle-invasive bladder cancer – state of the art. Aktuelle Urol 2010;41(5):307–15.; Sylvester R.J., van der Meijden A.P., Oosterlinck W. Predicting recurrence and progression in individual patients with stage Та T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77.; Hu Z., Mudaliar K., Quek M.L. et al. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Ann Diagn Pathol 2014;18(2):49—52.; Bobiński J., Lipiński M. EORTC risk tables–a new diagnostic tool in urology. Pol Merkur Lekarski 2009;27: 524–8.; Zehnder P., Thalmann G.N. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer. Curr Opin Urol 2013;23(5):423–8.; Hermann G.G., Horn T., Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159(1):91–4.; Platz C.E., Cohen M.B., Jones M.P. et al. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 1996;9:1035–9.; Cheng L., Weaver A.L., Neumann R.M. et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999;86:1035–43.; Angulo J.C., Lopez J.I., Grignon D.J., Sanchezhapado M. Muscularis mucosa differentiates 2 populations with different prognosis in stage T1 bladder-cancer. Urology 1995;45:47–53.; Holmang S., Hedelin H., Anderstrom C. et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800–4.; Orsola A., Trias I., Raventos C.X. et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48(2):231–8.; Rouprêt M., Seisen T., Compérat E. et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladdercarcinoma: French national multicenter study with central pathology review. J Urol 2013;189(6):2069–76.; Epstein J.I., Amin M.B., Reuter V.R., Mostofi F.K. The world health organization/ international society of urological patology consensus classification of urotelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22(12): 1435–48.; KawadT., Ebihara K, Suzuki T. et al. A new technique for transurethral resection of bladder tumors: rotational tumor resection using a new arched electrode. J Urol 1997;157(6):2225–6.; Naselli A., Introini C. En bloc transurethral resection of bladder lesions: a trick to retrieve specimens up to 4.5 cm. BJU Int 2012;109: 960–3.; Upadhyay R., Kapoor R., Srivastava A. et al. Does En-bloc transurethral resection of bladder tumor give a better yield in terms of presence of detrusor muscle in the biopsy specimen? Indian J Urol 2012;28(3):275–9.; Muto G., Collura D., Giacobbe A. et al. Thulium: yttrium-aluminum-garnet laser for en bloc resection of bladder cancer: clinical and histopathologic advantages. Urology 2014; 83(4):851–5.; Lodde M., Lusuardi L., Palermo S. et al. En bloc transurethral resection of bladder tumors: use and limits. Urology 2003;62(6): 1089–91.; Мартов А.Г., Ергаков Д.В., Байков Н.А. и др. Трансуретральное удаление опухолей мочевого пузыря единым блоком. Онкоурология 2015;11(2):41–50. [Martov A.G., Ergakov D.V., Baukov N.A. et al. Transurethral en bloc resection of bladder tumors. Onkourologiya = Oncourologiya 2015;11(2):41–50. (In Russ.].; Rodríguez-Alonso A., Pita-Fernández S., González-Carreró J., Nogueira-March J.L. Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki-67. Actas Urol Esp 2003;27(2):132–41.; https://oncourology.abvpress.ru/oncur/article/view/473

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/473
https://doi.org/10.17650/1726-9776-2015-11-4-42-50